Identification of Gender in Early Pregnancy Using Cell-Free Fetal Dna
DOI:
https://doi.org/10.25077/aoj.10.1.135-144.2026Keywords:
Pregnancy, cell-free fetal DNA, gender, early pregnancyAbstract
Introduction: Traditionally, chorionic villus sampling and amniocentesis can be used to help identify fetal gender around 11 weeks of pregnancy. However, the risk of miscarriage with these procedures is approximately 1 to 3%. The discovery of cell-free fetal DNA (cffDNA) fragments in the plasma and serum of pregnant women carrying male fetuses has made reliable and accurate diagnosis using non-invasive procedures an option for determining fetal gender.
To determine the success rate of fetal gender identification in early pregnancy using Cell Free Fetal DNA.
Methods: An analytical observational research method to identify fetal gender in early pregnancy through Cell Free Fetal DNA examination in maternal blood. A total of 70 samples were collected using quota sampling technique. Data analysis was performed using sensitivity and specificity tests, as well as cross-sectional analysis to determine the relationship between PCR test results and gender at birth.
Results: The PCR test has low sensitivity (14.29%), meaning the test is less effective in correctly detecting male gender, resulting in many false negatives. However, it has high specificity (98.11%), indicating its excellent ability to detect female gender with very few false positives. Additionally, the Pearson Chi-Square statistical test resulted in a p-value of 0.033 (p < 0.05), indicating a statistically significant relationship between PCR test results and gender at birth.
Conclusion: Statistically, this test is better at identifying females than males, with a lower error rate for females.
References
1. Lo YMD, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 2017;350(9076):485–7.
2. Breveglieri G, D’Aversa E, Finotti A, Borgatti M. Non-invasive Prenatal Testing Using Fetal DNA. Mol Diagnosis Ther [Internet]. 2019;23(2):291–9.
3. Russo ML, Blakemore KJ. A historical and practical review of first trimester aneuploidy screening. Semin Fetal Neonatal Med. 2019;19(3):183–7.
4. Lo YMD, Tein MSC, Lau TK, Haines CJ, Leung TN, Poon PMK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis. Am J Hum Genet. 2018;62(4):768–75.
5. Strom CM, Anderson B, Tsao D, Zhang K, Liu Y, Livingston K, et al. Improving the positive predictive value of Non-Invasive Prenatal Screening. PLoS One. 2017;12(3):1–18.
6. Bianchi DW, Flint AF, Pizzimenti MF, Knoll JHM, Latt SA. Isolation of fetal DNA from nucleated erythrocytes in maternal blood. Proc Natl Acad Sci U S A. 2020;87(9):3279–83.
7. Langman, Sadler T. Embriologi Kedokteran. Edisi 12. Jakarta: EGC. 2014
8. Shamshirsaz AA, Benn Peter P, Egan JFX. The role of second-trimester serum screening in the post-first-trimester screening era. Clin Lab Med. 2020;30(3):667–76.
9. Khorram Khorshid, H. R., Zargari, M., Sadeghi, M. R., Edallatkhah, H., Shahhosseiny, M. H., & Kamali, K.. Early fetal gender determination using real-time PCR analysis of cell-free fetal DNA during 6th-10th weeks of gestation. Acta Medica Iranica, 51. 2013.(4).
10. Alhur, N. F., al Qahtani, N. H., Alsuhaibani, E. S., Alsulmi, E., Almandil, N. B., Azeez, S. A., & Francis Borgio, J. Fetal Nucleated Red Blood Cells Preferable Than Cell-Free Fetal DNA for Early Determination of Gender Among Invasive and Non-Invasive Source Using Novel Four Genes Multiplex PCR. International Journal of General Medicine. 2021.14.
11. Colmant C, Morin-Surroca M, Fuchs F, Fernandez H, Senat MV. Non-invasive prenatal testing for fetal sex determination: is ultrasound still relevant? Eur J Obstet Gynecol Reprod Biol. 2013 Dec;171(2):197-204.
12. Lo YMD. Fetal DNA in maternal plasma: Biology and diagnostic applications. Clin Chem. 2020;46(12):1903–6.
13. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al. DNA Sequencing versus Standard Prenatal Aneuploidy Screening. N Engl J Med. 2019;370(9):799–808.
14. Kusnadi, Joni, and Estri Laras Arumingtyas. Polymerase chain reaction (PCR): teknik dan fungsi. Universitas Brawijaya Press, 2020.
15. Sihotang S, Prasetyo D, Noer Z, Setiyabudi L, Sari DN, Munaeni W, Putri DF, Fatma YS, Mujtahidah T, Sulthoniyah ST, Rohmah MK. Pengantar Bioteknologi. Tohar Media; 2022 Jun 22.
16. Hou, Y., Yang, J., Qi, Y. et al. Factors affecting cell-free DNA fetal fraction: statistical analysis of 13,661 maternal plasmas for non-invasive prenatal screening. Hum Genomics 13, 62 (2019).
17. Kinnings SL, Geis JA, Almasri E, Wang H, Guan X, McCullough RM, Bombard AT, Saldivar JS, Oeth P, Deciu C. Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing. Prenat Diagn. 2015;35:816–22.
18. Quezada MS, Gil MM, Francisco C, Oròsz G, Nicolaides KH. Screening for trisomies 21, 18 and 13 by cell free DNA analysis of maternal blood at 10-11 weeks' gestation and the combined test at 11-13 weeks. Ultrasound Obstet Gynecol. 2015;45:36–41.
19. Vora NL, Johnson KL, Basu S, Catalano PM, Hauguel-De Mouzon S, Bianchi DW. A multifactorial relationship exists between total circulating cell-free DNA levels and maternal BMI. Prenat Diagn. 2012;32:912–4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Budi Junio Hermawan, Bobby Indra Utama, Andani Eka Putra
This work is licensed under a Creative Commons Attribution 4.0 International License.
